Zum Hauptinhalt springen

Buprenorphin

09. Mai 2021 | Buprenorphin

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids Buprenorphine has a favorable safety profile because of its partial agonist and ceiling respiratory depression effects. However, there are poisoning dea…

22. April 2021 | Buprenorphin

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung Das Buprenorphin-haltige 6-Monatsimplantat Sixmo hat eine Zulassungsempfehlung für die Substitutionstherapie von stabilen Opiatabhängigen mit einem maximalen Buprenorphin-Bedar…

22. April 2021 | Buprenorphin

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist Was ist Sixmo und wofür wird es angewendet? Sixmo ist ein Implantat, das zur Behandlung einer Abhängigkeit von Opioiden wie Heroin oder Morphin angewendet wird…

11. April 2021 | Buprenorphin

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, Lancaster K, Larney S, Santo T Jr, Shanaha…

11. April 2021 | Buprenorphin

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence.

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. Hard B. Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. PMID: 33728083;…

11. April 2021 | Buprenorphin

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S. …

11. April 2021 | Buprenorphin

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route.

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), Clinical Pharmacology in…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten